Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

Epithelial-to-mesenchymal transition (EMT) may drive the escape of ALK-rearranged non-small-cell lung cancer (NSCLC) tumors from ALK-tyrosine kinase inhibitors (TKIs). We investigated whether first-generation ALK–TKI therapy-induced EMT promotes cross-resistance to new-generation ALK–TKIs and whethe...

Full description

Bibliographic Details
Main Authors: Sara Verdura, Jose Antonio Encinar, Eduard Teixidor, Antonio Segura-Carretero, Vicente Micol, Elisabet Cuyàs, Joaquim Bosch-Barrera, Javier A. Menendez
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
ALK
crizotinib
brigatinib
lorlatinib
silibinin
EMT
Online Access:https://www.mdpi.com/2072-6694/14/24/6101

Similar Items

Similar Items